Impel Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMPL research report →
Companyimpelpharma.com
Impel Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
- CEO
- Leonard S. Paolillo
- IPO
- 2021
- Employees
- 160
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $956.00K
- P/E
- -0.01
- P/S
- 0.08
- P/B
- -0.02
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 48.66%
- Op Margin
- -657.48%
- Net Margin
- -1023.08%
- ROE
- -3099.99%
- ROIC
- -122.46%
Growth & Income
- Revenue
- $12.65M · 1794.01%
- Net Income
- $-129,440,000 · -69.12%
- EPS
- $-5.52 · -5.34%
- Op Income
- $-83,184,000
- FCF YoY
- -42.30%
Performance & Tape
- 52W High
- $4.20
- 52W Low
- $0.02
- 50D MA
- $0.34
- 200D MA
- $0.97
- Beta
- 1.17
- Avg Volume
- 1.02M
Get TickerSpark's AI analysis on IMPL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 18, 23 | Smith Brandon D | other | 0 |
| Dec 15, 23 | Vivo Capital VIII, LLC | sell | 87,934 |
| Dec 18, 23 | Vivo Capital VIII, LLC | sell | 209,029 |
| Dec 19, 23 | Vivo Capital VIII, LLC | sell | 208,657 |
| Dec 15, 23 | Vivo Capital VIII, LLC | sell | 12,066 |
| Dec 18, 23 | Vivo Capital VIII, LLC | sell | 28,682 |
| Dec 19, 23 | Vivo Capital VIII, LLC | sell | 28,632 |
| Nov 30, 23 | BROOKFIELD Corp /ON/ | other | 445,294 |
| Nov 30, 23 | Oaktree GCP Fund Delaware Holdings, L.P. | other | 445,294 |
| Nov 30, 23 | Oaktree-TCDRS Strategic Credit, LLC | other | 445,294 |
Our IMPL Coverage
We haven't published any research on IMPL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMPL Report →